Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ.

JAMA. 1998 Dec 23-30;280(24):2077-82.

PMID:
9875874
[PubMed - indexed for MEDLINE]
2.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE.

Lancet. 1996 Dec 7;348(9041):1535-41.

PMID:
8950879
[PubMed - indexed for MEDLINE]
3.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.

Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.

PMID:
9531231
[PubMed - indexed for MEDLINE]
4.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.

JAMA. 1999 Oct 13;282(14):1344-52.

PMID:
10527181
[PubMed - indexed for MEDLINE]
5.

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.

PMID:
17190893
[PubMed - indexed for MEDLINE]
6.

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.

Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.

Arthritis Rheum. 1999 Jun;42(6):1246-54.

PMID:
10366118
[PubMed - indexed for MEDLINE]
Free Article
7.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

PMID:
7477143
[PubMed - indexed for MEDLINE]
Free Article
8.

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.

Chapurlat RD, Palermo L, Ramsay P, Cummings SR.

Osteoporos Int. 2005 Jul;16(7):842-8. Epub 2004 Dec 3.

PMID:
15580479
[PubMed - indexed for MEDLINE]
9.

Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial.

Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, Black D, Suryawanshi S, Hochberg M, Yates J; FIT Research Group.

J Am Geriatr Soc. 2002 Mar;50(3):409-15.

PMID:
11943033
[PubMed - indexed for MEDLINE]
10.

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.

Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM; Fracture Intervention Trial Research Group.

Mayo Clin Proc. 2005 Mar;80(3):343-9.

PMID:
15757015
[PubMed - indexed for MEDLINE]
11.

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124.

PMID:
10517716
[PubMed - indexed for MEDLINE]
12.

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.

Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group.

J Bone Miner Res. 2006 Feb;21(2):292-9. Epub 2005 Oct 31.

PMID:
16418785
[PubMed - indexed for MEDLINE]
13.
14.

Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.

Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR.

J Bone Miner Res. 2012 Aug;27(8):1804-10. doi: 10.1002/jbmr.1625.

PMID:
22492479
[PubMed - indexed for MEDLINE]
15.

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR.

Arch Intern Med. 2000 Jan 10;160(1):77-85.

PMID:
10632308
[PubMed - indexed for MEDLINE]
16.

Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.

Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, Santora AC 2nd, Black DM.

J Am Geriatr Soc. 2000 Mar;48(3):241-9.

PMID:
10733048
[PubMed - indexed for MEDLINE]
17.

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.

Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL; fracture intervention trial.

Diabetes Care. 2004 Jul;27(7):1547-53.

PMID:
15220226
[PubMed - indexed for MEDLINE]
18.

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.

Health Technol Assess. 2005 Jun;9(22):1-160. Review.

PMID:
15929857
[PubMed - indexed for MEDLINE]
Free Article
19.

The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.

Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC.

J Bone Miner Res. 2011 Apr;26(4):683-8. doi: 10.1002/jbmr.274.

PMID:
20939064
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E.

J Clin Endocrinol Metab. 2002 Mar;87(3):985-92.

PMID:
11889149
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk